Jingxin Pharmaceutical awarded the Medicilon DMPK team and the New Drug Registration Department the “Outstanding Contribution Team Award”
On May 25th, in recognition of the outstanding performance of Shanghai Medicilon Inc. in the development of new drugs, Dr. Yu Jiang, Dean of the Shanghai Academy of Jingxin Pharmaceutical and Dr. Jingjing Wang, the non-clinical director of the Shanghai Academy, visited the Medicilon in Chuansha Park, and awarded the Medicilon DMPK team and the New Drug Registration Department “Outstanding Contribution Team Award” and a letter of thanks.
About Jingxin Pharmaceutical
Founded in 1990, Zhejiang Jingxin Pharmaceutical Co., Ltd. (stock code: 002020) is a listed pharmaceutical company integrating R&D, production and sales. The company follows the business policy of “strengthening the main business of pharmaceuticals and developing medical devices”, and adheres to the core values of “pragmatic, innovative, inclusive, and win-win”. With the mission of “carefully guarding health”, Jingxin Pharmaceutical is committed to becoming a leader in the field of mental, nervous, cardiovascular and cerebrovascular diseases in China.
About Medicilon
Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China. Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research. Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support. By the end of 2022, Medicilon has provided new drug R&D services to more than 1,840 clients around the world, and participated in the R&D of 330 new drug projects that have been approved for clinical trials. Medicilon is proud to contribute to human health in the globe.
